Join us in World Innovators Meet 2022 New York to learn more about the trends in biotech sectors in both China and US.
The World Health Organization declared monkeypox a global health emergency on July 23 and warned the public of a potential massive outbreak before gay and bisexual communities, where many monkey cases have been reported. According to WHO, people of any sexual orientation can contract monkeypox. Previous data show that the United States used two types of smallpox vaccines that were 85% effective against monkeypox. However, the CDC is unsure whether either vaccine will be effective in the current outbreak. According to the CDC, people exposed to monkeypox and who have not received a smallpox vaccine within the last three years should get one as soon as possible. The WHO, on the other hand, does not currently recommend mass vaccination. Even though the efficacy of smallpox vaccines is unknown, investors' interest in monkeypox concept stock has grown, and many biotech companies with monkeypox-related business, such as GeoVax, Emergent BioSolutions, and Inovio, have been regarded as promising.
GeoVax (NASDAQ: GOVX) is a biotechnology company focused on developing an effective and safe vaccine. The company owns an MVA Vaccine Platform, and CEO David Dodd claims that its vaccines have been validated and registered and that one of the company's shots may prevent humans from contracting monkeypox. COVX was up 90% after the WHO declared monkeypox a global health emergency, trading at USD 2.12.
Emergent BioSolutions (NYSE: EBS) is an American multinational biopharmaceutical company focusing on vaccines and antibody therapeutics for infectious diseases and opioid overdoses. Chimerix's TEMBISA (brincidofovir), an FDA-approved antiviral agent against smallpox, was acquired by the company in May. Emergent BioSolutions has received a 9.3 million order for the TEMBISA and a Procurement Agreement worth approximately USD 25.3 million from the Public Health Agency of Canada. Emergent BioSolutions is up 7% to USD 33.77.
Inovio Pharmaceuticals Inc (NASDAQ: INO) is a biotechnology company focused on developing and commercializing DNA medicines for infectious, cancer, and HPV-related diseases. In 2010, the company revealed its experimental smallpox vaccine, which can protect non-human primates from monkeypox. Nonetheless, Inovio appears to have no monkeypox-related products on the market or in development.
Monkeypox concept stock is also gaining popularity in China. Beike Bio is the leading varicella vaccine manufacturer, with a 32% market share, a pipeline of influenza vaccines, rabies vaccines, and an incoming Zoster vaccine. Beike Bio was up by 13.47%, even though Beike states they do not have monkeypox-related products, and the varicella vaccine will not be effective against monkeypox. Shanghai ZJ Bio-Tech Co, a PCR-based molecular diagnostics solution provider, has recently soared due to their monkeypox test kit business.
Although China has not reported any monkeypox cases, we anticipate that the Chinese monkeypox vaccine market will be significant if the Monkeypox outbreak escalates and becomes a global pandemic like COVID-19. To enter China's monkeypox market, U.S. multinational corporations may face the challenge of conducting clinical trials locally and competing against local competitors. U.S. MNCs can significantly increase their chances of success in developing and selling their monkeypox vaccine by collaborating with local CRO companies in the R&D and clinical trial application stages.
If you want to learn more about the trends in biotech sectors in both China and US, join us in Manhattan on July 29-30, WIM (World Innovators Meet) 2022 and we will hold a panel, "From China to the World: China's Rapidly Expanding Biotechnology Industry". We invited Leo Tang, Advisor at BioSpark; Bing Yuan, Co-Founder, Chairman and CEO of OnCusp Therapeutics; Ying Huang, Chief Executive Officer of Legend Biotech; and Dahai Guo, Chairman and CEO of Zennova Pharmaceuticals; Sally (Yuanheng) Wang Liang, Board Member of Peplib, to the panel and to share their thoughts about cutting-edge biotechnology. Meanwhile, you could interact with like-minded business leaders, investors, scholars, and international relations experts on the key issues and opportunities facing U.S-China business collaboration and investments.
Over the course of 2 days, hear from speakers on the past, present, and future of innovation and exchange between China and the world–from trends in Blockchain, IoT, AI, 5G, Biotech and Fintech for 10 sessions, and network with 175 attendees representing top institutional investors, venture funds, and investment firms.
